ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3189

Patient Perceptions of Glucocorticoid Side Effects: A Survey of Users in an Online Health Community

Ruth Costello1, Rikesh Patel1, Jennifer Humphreys1, John McBeth1 and William G Dixon2, 1Manchester Academic Health Science Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 2Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: steroids

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 16, 2016

Title: Epidemiology and Public Health III: Psoriatic Arthritis and More

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Glucocorticoids (GC) are widely used to treat inflammatory diseases, but are known to have many side effects. Patients’ perspectives of side effects are known to influence treatment decisions and adherence, yet few studies have investigated which side effects are important to patients. The aim of this study was to identify the side effects most important to GC users through a survey of a UK online health community (healthunlocked.com).

Methods: A short survey about GC use popped up when UK users viewed posts discussing steroids on healthunlocked.com. Responders were eligible if they were currently taking, or had taken GCs within the last month. Within the survey, responders had to score the importance of listed side effects from 1 to 10, with 10 being of high importance to them. The side effects shown in table 1 were listed alphabetically, with examples or descriptions as required. For each side effect, histograms were plotted, and the median rating and inter-quartile range (IQR) was determined. Side effects were ranked by median ranking (largest to smallest) and then IQR (smallest to largest) for those with the same median. The scores were categorised as low (scores 1-3), medium (scores 4-7) and high (scores 8-10) importance.

Results: There were 604 responders who completed the survey. The majority were over 50 years old (81%) and female (86%). Histograms of side effect scores showed a skew towards high importance for weight gain, a U-shaped distribution for CVD, diabetes, eye disease and infections, and a skew towards low importance for acne (Figure 1). When ranked the side effect of most importance to responders was weight gain (median score=9, IQR 6, 10) followed by insomnia and moon face with equal median score (8) and IQR (5, 10). Several side effects had the same median score of 8, but distribution across categories varied. Three clinically serious side effects: cardiovascular disease, diabetes and infection, were ranked of lower importance but had wide ranging scores (median score=8, IQR 1, 10). Acne was of least importance to responders (median score=1, IQR 1, 6) (Table 1).

Conclusion: The three most highly rated side effects were not clinically serious but remained important to patients, perhaps reflecting their impact on quality of life and their high prevalence. The importance of these less serious but potentially high impact side effects should be taken into consideration when discussing treatment options and planning future GC safety studies. Table 1: Median, inter-quartile range, rank and categories of side effect scores.

Side effect                        

Median(IQR)

Rank

Low (score 1-3) N (%)

Medium (score 4-7) N (%)

High (scores 8-10) N (%)

 Weight gain

9 (6, 10)

1

74 (12.3)

145 (24)

385 (63.7)

 Insomnia

8 (5, 10)

2

75 (12.4)

210 (34.8)

319 (52.8)

Moon face

8 (5, 10)

2

125 (20.7)

149 (24.7)

330 (54.6)

 High blood pressure

8 (4, 10)

4

150 (24.8)

138 (22.8)

316 (52.3)

 Reduced bone strength

8 (4, 10)

4

133 (22)

134 (22.2)

337 (55.8)

 Eye disease

8 (3, 10)

6

164 (27.2)

93 (15.4)

347 (57.5)

 Cardiovascular disease

8 (1, 10)

7

216 (35.8)

56 (9.3)

332 (55)

 Diabetes

8 (1, 10)

7

206 (34.1)

86 (14.2)

312 (51.7)

 Infections

8 (1, 10)

7

182 (30.1)

116 (19.2)

306 (50.7)

 Changes in mood

7 (5, 9)

10

110 (18.2)

239 (39.6)

255 (42.2)

 Skin changes

7 (5, 9)

10

109 (18)

214 (35.4)

281 (46.5)

 Palpitations

7 (4, 9)

12

125 (20.7)

212 (35.1)

267 (44.2)

 Indigestion

6 (3, 8)

13

152 (25.2)

276 (45.7)

176 (29.1)

 Acne

1 (1, 6)

14

359 (59.4)

138 (22.8)

107 (17.7)

Figure 1:  Histograms of side effect ratings. 1=rating of lowest importance, 10=rating of highest importance.


Disclosure: R. Costello, None; R. Patel, None; J. Humphreys, None; J. McBeth, None; W. G. Dixon, None.

To cite this abstract in AMA style:

Costello R, Patel R, Humphreys J, McBeth J, Dixon WG. Patient Perceptions of Glucocorticoid Side Effects: A Survey of Users in an Online Health Community [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/patient-perceptions-of-glucocorticoid-side-effects-a-survey-of-users-in-an-online-health-community/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-perceptions-of-glucocorticoid-side-effects-a-survey-of-users-in-an-online-health-community/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology